文献速递乳腺癌

BRCA1介导的铁死亡双重调控揭示BRCA1缺陷癌症对GPX4和PARP联合抑制的脆弱性

BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
PubMed 文献 · Cancer Discov · 2024-01-01

BRCA1通过促进VDAC3和GPX4转录发挥铁死亡双重调控作用;BRCA1缺陷使细胞对erastin诱导的铁死亡抵抗,但对GPX4抑制剂诱导的铁死亡敏感;NCOA4介导的铁蛋白自噬与GPX4诱导缺陷使PARP抑制剂与GPX4抑制剂联用可在BRCA1缺陷癌细胞中触发强烈铁死亡;BRCA1突变乳腺癌PARP抑制剂耐药异种移植瘤GPX4表达降低且对PARP与GPX4联合抑制高度敏感。

要点

  • BRCA1促进VDAC3和GPX4转录,缺陷时对erastin诱导铁死亡抵抗、对GPX4抑制剂敏感。
  • NCOA4介导铁蛋白自噬与GPX4诱导缺陷使PARP抑制剂联合GPX4抑制剂在BRCA1缺陷细胞中触发铁死亡。
  • BRCA1突变乳腺癌PARP抑制剂耐药异种移植瘤GPX4表达降低且对PARP与GPX4联合抑制高度敏感。

核心结论

  • BRCA1缺陷诱导对PARP与GPX4联合抑制的铁死亡脆弱性,为克服BRCA1缺陷癌症PARP抑制剂耐药提供治疗策略。

研究设计与样本

  • 基础与转化研究,包含细胞实验及来源于BRCA1突变乳腺癌PARP抑制剂耐药患者的异种移植瘤。

主要发现

  • BRCA1促进VDAC3和GPX4转录;BRCA1缺陷促进细胞对erastin诱导铁死亡的抵抗,但使癌细胞对GPX4抑制剂诱导的铁死亡敏感。
  • NCOA4介导的铁蛋白自噬和缺陷的GPX4诱导使BRCA1缺陷癌细胞在PARP抑制剂与GPX4抑制剂联合处理时发生强烈铁死亡。
  • 来源于BRCA1突变乳腺癌PARP抑制剂耐药患者的异种移植瘤GPX4表达降低,且对PARP与GPX4联合抑制高度敏感。

临床怎么用

  • 作者认为BRCA1缺陷诱导对PARP与GPX4联合抑制的铁死亡脆弱性,并据此提出克服BRCA1缺陷癌症PARP抑制剂耐药的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) limits the therapeutic efficacy of PARP inhibition in treating breast cancer susceptibility gene 1 (BRCA1)-deficient cancers. Here we reveal that BRCA1 has a dual role in regulating ferroptosis. BRCA1 promotes the transcription of voltage-dependent anion channel 3 (VDAC3) and glutathione peroxidase 4 (GPX4); consequently, BRCA1 deficiency promotes cellular resistance to erastin-induced ferroptosis but sensitizes cancer cells to ferroptosis induced by GPX4 inhibitors (GPX4i). In addition, nuclear receptor coactivator 4 (NCOA4)-mediated ferritinophagy and defective GPX4 induction unleash potent ferroptosis in BRCA1-deficient cancer cells upon PARPi and GPX4i co-treatment. Finally, we show that xenograft tumors derived from patients with BRCA1-mutant breast cancer with PARPi resistance exhibit decreased GPX4 expression and high sensitivity to PARP and GPX4 co-inhibition. Our results show that BRCA1 deficiency induces a ferroptosis vulnerability to PARP and GPX4 co-inhibition and inform a therapeutic strategy for overcoming PARPi resistance in BRCA1-deficient cancers. Significance: BRCA1 deficiency promotes resistance to erastin-induced ferroptosis via blocking VDAC3 yet renders cancer cells vulnerable to GPX4i-induced ferroptosis via inhibiting GPX4. NCOA4 induction and defective GPX4 further synergizes GPX4i with PARPi to induce ferroptosis in BRCA1-deficient cancers and targeting GPX4 mitigates PARPi resistance in those cancers. See related commentary by Alborzinia and Friedmann Angeli, p. 1372.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lei G, Mao C, Horbath AD, et al. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers. Cancer Discov. 2024. PMID: 38552003. doi:10.1158/2159-8290.CD-23-1220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。